

CURRICULUM VITAE

Version date:	July 10, 2019
---------------	---------------

A. GENERAL INFORMATION

Required Information:

Name:	Gregory Riely
Office address:	885 Second Ave, Room 1026, New York, NY 10065
Office telephone:	646-888-4199
Office fax:	646-888-4262

B. EDUCATIONAL BACKGROUND

1. Academic Degree(s): B.A. and higher; institution name and location; dates attended; date of award. Expand the table as needed.

Degree (abbreviation)	Institution Name and Location	Dates attended	Year Awarded
BA	The Johns Hopkins University, Baltimore, Maryland	1990-1994	1994
PhD	Case Western Reserve University, Cleveland, Ohio	1994-1999	1999
MD	Case Western Reserve University, Cleveland, Ohio	1994-2001	2001

2. Post-doctoral training (include residency/fellowships): In chronological order beginning with postdoctoral training positions; include full titles, ranks and inclusive dates held. Expand the tables as needed.

Title	Institution name and location	Dates held
Intern	New York Presbyterian Hospital – Weill Cornell Center, New York	2001-2002
Resident	New York Presbyterian Hospital – Weill Cornell Center, New York	2002-2003
Fellow	Memorial Hospital for Cancer & Allied Diseases, New York	2003-2006
Fellow in Medicine	Weill Cornell Medical College, New York	2003-2006

C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure: Every physician appointed to the Hospital staff, except interns, and aliens in the US via non-immigrant visas, must have a New York State license or a temporary certificate in lieu of the license.

a. State	Number	Date of issue	Date of last registration
New York	228564	5/29/2003	5/31/2018

b. If no license:	
1. Do you have a temporary certificate?	Yes/No/NA
2. Have you passed the examination for foreign medical school graduates?	Yes/No/NA

c. DEA number (optional):	BR8357306
d. NPI number (optional):	1770648875

2. Board Certification

Full Name of Board	Certificate #	Dates of Certification (mm/dd/yyyy) – Start and End Dates
American Board of Internal Medicine – Internal Medicine	228350	Passed certification exams in 2004, 2014, currently maintaining certification.
American Board of Internal Medicine – Medical Oncology	228350	Passed certification exams in 2006, 2016, currently maintaining certification.

D. PROFESSIONAL POSITIONS AND EMPLOYMENT 1. Academic positions (teaching and research)

Title	Institution name and location	Dates held
Assistant Member (Level 1)	Memorial Sloan-Kettering Cancer Center, New York	2007-2010
Instructor	Weill Cornell Medical College, New York	2007-2010
Assistant Member	Memorial Sloan-Kettering Cancer Center, New York	2010-2014

Assistant Professor	Weill Cornell Medical College, New York	2010-2014
Associate Member	Memorial Sloan-Kettering Cancer Center, New York	2014-Present
Associate Professor	Weill Cornell Medical College, New York	2015-Present

2. Hospital positions (e.g., attending physician)

Title	Institution name and location	Dates held
Assistant Attending Physician	Memorial Hospital for Cancer & Allied Diseases, New York, New York	2007-2014
Associate Attending Physician	Memorial Hospital for Cancer & Allied Diseases, New York, New York	2014-Present

E. EMPLOYMENT STATUS (current or anticipated)

Name of Employer(s): Memorial Sloan-Kettering Cancer Center
Employment Status (choose one, delete the others): Full-time salaried by Cornell-affiliated hospital

F. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation:	Memorial Hospital for Cancer and Allied Diseases
2. Other Hospital Affiliations:	
3. Other Institutional Affiliations:	Weill Cornell Medical College

G. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

i.e. - Journal Reviewer, Editorial Boards, Study Sections, Invited Presentations

Activity / Responsibility	Dates
American Society of Clinical Oncology Reviewer – ASCO – SAP	2008
American Society of Clinical Oncology Cancer.net Advisory Panel	2008-present
American Society of Clinical Oncology Conquer Cancer Foundation Grants Selection Committee	2012-2015

American Society of Clinical Oncology Scientific Program Committee	2013-2016
American Society of Clinical Oncology, Scientific Program Committee, Lung Cancer - Non-Small Cell Local-regional, Track Leader	2014-2015
American Society of Clinical Oncology, Non-Small Cell Lung Cancer Guidelines Committee	2017-present
International Association for the Study of Lung Cancer -Lung Adenocarcinoma Classification Committee	2009-2011
International Association for the Study of Lung Cancer -International Scientific Abstract Review Committee	2013
National Comprehensive Cancer Network -Non-Small Cell Lung Cancer guidelines panel	2010-present
National Comprehensive Cancer Network -Thymic Malignancies guidelines panel	2010-present
American Joint Committee on Cancer, Thoracic Expert Panel	2014-2016
Department of Defense Congressionally Directed Medical Research Programs, Grant Reviewer	2015
European Society for Medical Oncology, ESMO 2016 Scientific Committee, NSCLC-Metastatic	2016
European Society for Medical Oncology, ESMO Asia 2016, Scientific Committee, Thoracic Cancers	2016
United States Food and Drug Administration, Oncologic Drugs Advisory Committee	2016-2020
American Society of Clinical Oncology, Scientific Program Committee, Lung Cancer - Non-Small Cell Local-regional, Track Leader	2017-2019 2018-2019
American Association of Cancer Research, Project GENIE	2019-present

H. PROFESSIONAL MEMBERSHIPS

Include medical and scientific societies.

Member/Officer/Fellow/Role	Organization	Dates
Member	American Society of Clinical Oncology	2004- present
Member	International Association for the Study of Lung Cancer	2006-present

I. HONORS AND AWARDS

Name of award	Date awarded
Dean's List, The Johns Hopkins University	1991-1993
Provost's Award for Undergraduate Research and Excellence, The Johns Hopkins University	1993
Fellowship in the Medical Scientist Training Program, Case Western Reserve University	1994-2001
AACR/ASCO Clinical Trials Workshop, Vail, Colorado	2005
ASCO Young Investigator Award	2007

J. BIBLIOGRAPHY

1. Articles in professional peer-reviewed journals

1. Villa-Garcia M, Li L, **Riely G**, Bray PF. Isolation and characterization of a TATAless promoter for the human beta 3 integrin gene. *Blood*. 1994;83(3):668-676. PMID: 8298129.
2. Rachmilewitz J, **Riely GJ**, Tykocinski ML. Placental protein 14 functions as a direct T-cell inhibitor. *Cell Immunol*. 1999;191(1):26-33. PMID: 9918684.
3. **Riely GJ**, Rachmilewitz J, Koo PH, Tykocinski ML. alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14. *Biochem J*. 2000;351 Pt 2:503-508. PMCID: 1221387. PMID: 11023837.
4. Rachmilewitz J, **Riely GJ**, Huang JH, Chen A, Tykocinski ML. A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds. *Blood*. 2001;98(13):3727-3732. PMID: 11739178.
5. Rachmilewitz J, Borovsky Z, Mishan-Eisenberg G, Yaniv E, **Riely GJ**, Tykocinski ML. Focal localization of placental protein 14 toward sites of TCR engagement. *J Immunol*. 2002;168(6):2745-2750. PMID: 11884441.
6. Rachmilewitz J, Borovsky Z, **Riely GJ**, Miller R, Tykocinski ML. Negative regulation of T cell activation by placental protein 14 is mediated by the tyrosine phosphatase receptor CD45. *J Biol Chem*. 2003;278(16):14059-14065. PMID: 12556471.
7. Pao W, Miller VA, Politi KA, **Riely GJ**, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med*. 2005;2(3):e73. PMCID: 549606. PMID: 15737014.
8. Pao W, Wang TY, **Riely GJ**, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med*. 2005;2(1):e17. PMCID: 545207. PMID: 15696205.
9. Balak MN, Gong Y, **Riely GJ**, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res*. 2006;12(21):6494-6501. PMID: 17085664.
10. Milton DT, **Riely GJ**, Pao W, Miller VA, Kris MG, Heelan RT. Molecular on/off switch. *J Clin Oncol*. 2006;24(30):4940-4942. PMID: 17050880.
11. Pham D, Kris MG, **Riely GJ**, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. *J Clin Oncol*. 2006;24(11):1700-1704. PMID: 16505411.
12. **Riely GJ**, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Clinical course of patients with non-small cell lung

cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clin Cancer Res.* 2006;12(3 Pt 1):839-844. PMID: 16467097.

13. Bean J, Brennan C, Shih JY, **Riely G**, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci U S A.* 2007;104(52):20932-20937. PMCID: 2409244. PMID: 18093943.
14. Milton DT, **Riely GJ**, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. *Cancer.* 2007;110(3):599-605. PMID: 17577220.
15. **Riely GJ**, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. *Lung Cancer.* 2007;55(2):181-185. PMID: 17092603.
16. **Riely GJ**, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. *Clin Cancer Res.* 2007;13(17):5150-5155. PMID: 17785570.
17. Bean J, **Riely GJ**, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. *Clin Cancer Res.* 2008;14(22):7519-7525. PMCID: 2596620. PMID: 19010870.
18. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, **Riely GJ**, Yeap BY, Halmos B, Kim JH, Janne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. *Clin Cancer Res.* 2008;14(21):7060-7067. PMCID: 2596582. PMID: 18981003.
19. Li AR, Chitale D, **Riely GJ**, Pao W, Miller VA, Zakowski MF, Rusch V, Kris MG, Ladanyi M. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. *J Mol Diagn.* 2008;10(3):242-248. PMCID: 2329789. PMID: 18403609.
20. Marks JL, Golas B, Kirchoff T, Miller VA, **Riely GJ**, Offit K, Pao W. EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. *J Thorac Oncol.* 2008;3(7):805. PMID: 18594331.
21. Miller VA, **Riely GJ**, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. *J Clin Oncol.* 2008;26(9):1472-1478. PMID: 18349398.
22. Motoi N, Szoke J, **Riely GJ**, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include

the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. *Am J Surg Pathol*. 2008;32(6):810-827. PMID: 18391747.

23. **Riely GJ**, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. *Clin Cancer Res*. 2008;14(18):5731-5734. PMID: 18794081.
24. Rizvi NA, **Riely GJ**, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG. Phase I/II trial of weekly intravenous 130-nm albuminbound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol*. 2008;26(4):639-643. PMID: 18235124.
25. Girard N, Shen R, Guo T, Zakowski MF, Heguy A, **Riely GJ**, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. *Clin Cancer Res*. 2009;15(22):6790-6799. PMID: 19861435.
26. Huang J, Rizk NP, Travis WD, **Riely GJ**, Park BJ, Bains MS, Dycoco J, Flores RM, Downey RJ, Rusch VW. Comparison of patterns of relapse in thymic carcinoma and thymoma. *J Thorac Cardiovasc Surg*. 2009;138(1):26-31. PMID: 19577051.
27. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, **Riely GJ**, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. *Clin Cancer Res*. 2009;15(16):5267-5273. PMID: 19671843.
28. **Riely GJ**, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. *J Clin Oncol*. 2009;27(2):264-270. PMID: 19047285.
29. Zhao B, James LP, Moskowitz CS, Guo P, Ginsberg MS, Lefkowitz RA, Qin Y, **Riely GJ**, Kris MG, Schwartz LH. Evaluating variability in tumor measurements from sameday repeat CT scans of patients with non-small cell lung cancer. *Radiology*. 2009;252(1):263-272. PMID: 19561260.
30. Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, Orlow I, Yatabe Y, Nafa K, Ladanyi M, Viale A, Kris MG, **Riely G**, Miller V, Klein RJ, Matsuo K, Pao W. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internetbased blood collection protocol: a preliminary report. *Clin Cancer Res*. 2010;16(2):755-763. PMID: 20068085.
31. Girard N, Teruya-Feldstein J, Payabyab EC, **Riely GJ**, Rusch VW, Kris MG, Zakowski MF. Insulin-like growth factor-1 receptor expression in thymic malignancies. *J Thorac Oncol*. 2010;5(9):1439-1446. PMID: 20736806.
32. Janjigian YY, McDonnell K, Kris MG, Shen R, Sima CS, Bach PB, Rizvi NA, **Riely GJ**. Pack-years of cigarette smoking as a prognostic factor in patients with stage

- IIIB/IV nonsmall cell lung cancer. *Cancer*. 2010;116(3):670-675. PMID: 2815173. PMID: 20029977.
33. Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, **Riely GJ**, Heelan RT, Arcila ME, Miller VA. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. *J Thorac Oncol*. 2010;5(10):1623-1629. PMID: 20871262.
 34. Yeo WL, **Riely GJ**, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for nonsmall cell lung cancers with EGFR mutations. *J Thorac Oncol*. 2010;5(7):1048-1053. PMID: 2893286. PMID: 20512075.
 35. Arcila ME, Oxnard GR, Nafa K, **Riely GJ**, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. *Clin Cancer Res*. 2011;17(5):1169-1180. PMID: 3070951. PMID: 21248300.
 36. Bott MJ, Wang H, Travis W, **Riely GJ**, Bains M, Downey R, Rusch V, Huang J. Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. *Ann Thorac Surg*. 2011;92(6):1984-1991; PMID: 22115206.
 37. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, **Riely GJ**. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. *Clin Cancer Res*. 2011;17(19):6298-6303. PMID: 21856766.
 38. D'Angelo SP, Pietanza MC, Johnson ML, **Riely GJ**, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. *J Clin Oncol*. 2011;29(15):2066-2070. PMID: 3296671. PMID: 21482987.
 39. Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, **Riely GJ**. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. *Clin Cancer Res*. 2011;17(8):2521-2527. PMID: 21248303.
 40. Johnson ML, **Riely GJ**, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. *J Thorac Oncol*. 2011;6(6):1128-1131. PMID: 3230574. PMID: 21623279.
 41. Oxnard GR, Arcila ME, Sima CS, **Riely GJ**, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. *Clin Cancer Res*. 2011;17(6):1616-1622. PMID: 3060283. PMID: 21135146.
 42. Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, **Riely GJ**, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or

- gefitinib. *Clin Cancer Res.* 2011;17(19):6322-6328. PMCID: 3186869. PMID: 21831955.
43. Oxnard GR, Zhao B, Sima CS, Ginsberg MS, James LP, Lefkowitz RA, Guo P, Kris MG, Schwartz LH, **Riely GJ**. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. *J Clin Oncol.* 2011;29(23):3114-3119. PMCID: 3157977. PMID: 21730273.
 44. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, **Riely GJ**. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol.* 2011;29(15):2046-2051. PMCID: 3107760. PMID: 21483012.
 45. Paik PK, James LP, **Riely GJ**, Azzoli CG, Miller VA, Ng KK, Sima CS, Heelan RT, Kris MG, Moore E, Rizvi NA. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane(R)) given as a two-hour infusion. *Cancer Chemother Pharmacol.* 2011;68(5):1331-1337. PMID: 21461889.
 46. Reinersman JM, Johnson ML, **Riely GJ**, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. *J Thorac Oncol.* 2011;6(1):28-31. PMCID: 3337520. PMID: 21107288.
 47. Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, **Riely GJ**, Travis WD, Zakowski MF, Moreira AL. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. *J Thorac Oncol.* 2011;6(3):451-458. PMID: 21266922.
 48. **Riely GJ**, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. *J Thorac Oncol.* 2011;6(8):1435-1437. PMID: 21847063.
 49. Shaw AT, Yeap BY, Solomon BJ, **Riely GJ**, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol.* 2011;12(11):1004-1012. PMCID: 3328296. PMID: 21933749.
 50. Sigel CS, Moreira AL, Travis WD, Zakowski MF, Thornton RH, **Riely GJ**, Rekhtman N. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. *J Thorac Oncol.* 2011;6(11):1849-1856. PMID: 21841504.
 51. Yoshizawa A, Motoi N, **Riely GJ**, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Mod Pathol.* 2011;24(5):653-664. PMID: 21252858.
 52. Chaft JE, Arcila ME, Paik PK, Lau C, **Riely GJ**, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG. Coexistence of PIK3CA and other oncogene

- mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. *Mol Cancer Ther.* 2012;11(2):485-491. PMID: 22135231.
53. Chaft JE, Rekhtman N, Ladanyi M, **Riely GJ**. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. *J Thorac Oncol.* 2012;7(4):768-769. PMID: 22425930.
 54. Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, **Riely G**, Pao W. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. *Eur Respir J.* 2012;39(2):366-372. PMID: 21778168.
 55. Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL, Yoshizawa A, **Riely GJ**, Rusch VW, Adusumilli PS, Travis WD. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol.* 2012 Aug;25(8):1117-27. PMID: 22499226.
 56. Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG, **Riely GJ**. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. *Cancer.* 2012 Dec 1;118(23):5840-7. PMID: 22605530.
 57. Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, **Riely GJ**, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. *J Thorac Oncol.* 2012 May;7(5):856-65.
 58. Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, **Riely GJ**, Kris MG, Krug LM. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clin Cancer Res.* 2012;18(4):1138-1145. PMID: 22228633.
 59. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidiás P, Yang JC, Miller VA, **Riely GJ**, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. *Proc Natl Acad Sci U S A.* 2012 Jul 31;109(31):E2127-33.
 60. Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, **Riely GJ**. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. *Cancer.* 2013 Jan 15;119(2):356-62.
 61. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, **Riely GJ**, Monica V, Yeap BY, Scagliotti GV. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. *Ann Oncol.* 2013 Jan;24(1):59-66.
 62. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, **Riely GJ**, Solomon B, Ou SH, Kim DW, Salgia R, Fidiás P, Engelman JA, Gandhi L, Jänne PA, Costa

- DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol.* 2012 Oct;13(10):1011-9.
63. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, **Riely GJ**, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation. *Cancer Discov.* 2012 Oct;2(10):922-933
 64. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, **Riely GJ**, Kris MG, Zakowski MF, Ladanyi M. Molecular Epidemiology of EGFR and KRAS Mutations in 3026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-related KRAS-mutant Cancers. *Clin Cancer Res.* 2012 Nov 15;18(22):6169-77
 65. D'Angelo SP, Janjigian YY, Ahye N, **Riely GJ**, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. *J Thorac Oncol.* 2012 Dec;7(12):1815-22.
 66. Varghese AM, Sima CS, Chaft JE, Johnson ML, **Riely GJ**, Ladanyi M, Kris MG. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. *J Thorac Oncol.* 2013 Jan;8(1):123-5.
 67. Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, **Riely GJ**. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. *J Thorac Oncol.* 2013 Mar;8(3):346-51.
 68. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, **Riely GJ**. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. *Clin Cancer Res.* 2013 Apr 15;19(8):2240-7.
 69. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, **Riely GJ**, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA Jr, Pao W. Characteristics of Lung Cancers Harboring NRAS Mutations. *Clin Cancer Res.* 2013 May 1;19(9):2584-2591
 70. Rekhtman N, Ang DC, **Riely GJ**, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. *Mod Pathol.* 2013 Oct;26(10):1307-19.
 71. Kim HR, Ahn JR, Lee JG, Bang DH, Ha SJ, Hong YK, Kim SM, Nam KC, Rha SY, Soo RA, **Riely GJ**, Kim JH, Cho BC. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. *Yonsei Med J.* 2013 Jul;54(4):865-74.
 72. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B,

- Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, **Riely GJ**, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*. 2013 Jun 20;368(25):2385-94.
73. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, **Riely GJ**, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2013 Aug 1;19(15):4273-81.
74. Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, **Riely GJ**, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA, Paik PK. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. *Cancer Chemother Pharmacol*. 2013 Aug;72(2):453-61.
75. Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, **Riely GJ**, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA. Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers. *J Thorac Oncol*. 2013 Aug;8(8):1084-90.
76. Rekhtman N, Borsu L, Reva B, Arcila M, **Riely GJ**, Ladanyi M, Drilon A. Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. *J Thorac Oncol*. 2014 Jan;9(1):e1-3.
77. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, **Riely GJ**, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. *Sci Transl Med*. 2013 Dec 18;5(216):216
78. Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, **Riely GJ**, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2014 Feb;15(2):191-200.
79. Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, **Riely GJ**, Rusch VW, Adusumilli PS, Travis WD. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. *Am J Surg Pathol*. 2014 Apr;38(4):448-60.
80. Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW, **Riely GJ**. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. *Ann Oncol*. 2014 Feb;25(2):415-22.

81. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, **Riely GJ**. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. *Ann Oncol*. 2014 Feb;25(2):423-8.
82. Rimner A, Gomez DR, Wu AJ, Shi W, Yorke ED, Moreira AL, Rice D, Komaki R, Rosenzweig KE, **Riely GJ**, Huang J. Failure patterns relative to radiation treatment fields for stage II-IV thymoma. *J Thorac Oncol*. 2014 Mar;9(3):403-9.
83. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, **Riely GJ**, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med*. 2014 Mar 27;370(13):1189-97.
84. Gerber NK, Yamada Y, Rimner A, Shi W, **Riely GJ**, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ. Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma. *Int J Radiat Oncol Biol Phys*. 2014 Jun 1;89(2):322-9.
85. Yu HA, Arcila ME, Harlan Fleischut M, Stadler Z, Ladanyi M, Berger MF, Robson M, **Riely GJ**. Germline EGFR T790M mutation found in multiple members of a familial cohort. *J Thorac Oncol*. 2014 Apr;9(4):554-8. PMID: 24736080
86. Varghese AM, Zakowski MF, Yu HA, Won HH, **Riely GJ**, Krug LM, Kris MG, Rekhtman N, Ladanyi M, Wang L, Berger MF, Pietanza MC. Small-cell lung cancers in patients who never smoked cigarettes. *J Thorac Oncol*. 2014 Jun;9(6):892-6. PMID: 24828667
87. Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, **Riely GJ**, Arcila ME, Kris MG, Rusch VW, Adusumilli PS, Travis WD. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. *Am J Surg Pathol*. 2014 Aug;38(8):1118-27. PMID: 25029118
88. Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, **Riely GJ**, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. *Cancer Discov*. 2014 Sep;4(9):1036-45. PMID: 25074459
89. Gadgeel SM, Gandhi L, **Riely GJ**, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boissier F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. *Lancet Oncol*. 2014 Sep;15(10):1119-28. PMID: 25153538
90. Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, **Riely GJ**, Kris MG, Krug LM, Pietanza MC. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. *Lung Cancer*. 2014 Aug 17. [Epub ahead of print] PMID: 25194640
91. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, **Riely GJ**, VarellaGarcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P,

- Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. *N Engl J Med*. 2014 Sep 27. [Epub ahead of print] PMID: 25264305
92. Moreira AL, Won HH, McMillan R, Huang J, **Riely GJ**, Ladanyi M, Berger MF. Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis. *J Thorac Oncol*. 2015 Feb;10(2):373-80. PMID: 25299233
 93. Halpenny DF, **Riely GJ**, Hayes S, Yu H, Zheng J, Moskowitz CS, Ginsberg MS. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? *Lung Cancer*. 2014 Nov;86(2):190-4. PMID: 25312988
 94. Litvak AM, Woo K, Hayes S, Huang J, Rimmer A, Sima CS, Moreira AL, Tsukazan M, **Riely GJ**. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. *J Thorac Oncol*. 2014 Dec; 9(12):1810-5. PMID: 25393794
 95. Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, **Riely GJ**. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. *J Thorac Oncol*. 2014 Nov 20. PMID: 25415430
 96. Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, **Riely GJ**. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. *J Thorac Oncol*. 2014 Nov;9(11):1669-74. PMID: 25436800
 97. Costa DB, Shaw AT, Ou SH, Solomon BJ, **Riely GJ**, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. *J Clin Oncol*. 2015 Jan 26. pii: JCO.2014.59.0539. PMID: 25624436
 98. Yu HA, Sima CS, Hellmann MD, Naidoo J, Busby N, Rodriguez K, **Riely GJ**, Kris MG. Differences in the survival of patients with recurrent versus de novo metastatic KRASmutant and EGFR-mutant lung adenocarcinomas. *Cancer*. 2015 Jun 15;121(12):2078-82. PMID: 2578186
 99. Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, **Riely GJ**. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *J Clin Oncol*. 2015 May 20;33(15):1666-73.
 100. Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, **Riely GJ**, Kris MG, Arcila ME, Yu HA. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. *Cancer*. 2015 Jun 10. PMID: 26096453
 101. Yu HA, Tian SK, Drilon AE, Borsu L, **Riely GJ**, Arcila ME, Ladanyi M. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. *JAMA Oncol*. 2015 May 7. PMID: 26181354
 102. Sundaresan TK, Sequist LV, Heymach JV, **Riely GJ**, Janne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu H, Wei W,

- Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. *Clin Cancer Res.* 2016 Mar 1;22(5):1103-10. PMID: 26446944
103. Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, **Riely GJ**, Druker BJ, O'Hare T, Ladanyi M, Davare MA. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. *Clin Cancer Res.* 2015 Dec 16. PMID: 26673800
104. Shaw AT, Gandhi L, Gadgeel S, **Riely GJ**, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH. Alectinib in ALK-positive, crizotinib-resistant, nonsmall-cell lung cancer: a single-group, multicentre, phase 2 trial. *Lancet Oncol.* 2016 Feb;17(2):234-42. PMID: 26708155
105. Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, **Riely GJ**, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. *Clin Lung Cancer.* 2016 Jan 21. PMID: 26898325
106. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, **Riely GJ**, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. *Lancet Oncol.* 2016 Mar 10. PMID: 26973324
107. Drilon A, Bergagnini I, Delasos L, Sabari J, Woo K, Plodkowski A, Wang L, Hellmann M, Joubert P, Sima C, Smith R, Somwar R, Rekhtman N, Ladanyi M, **Riely GJ**, Kris MG. Clinical Outcomes with Pemetrexed-Based Systemic Therapies in RET-rearranged Lung Cancers. *Ann Oncol.* 2016 Apr 7. PMID: 27056998
108. Planchard D, Kim TM, Mazieres J, Quoix E, **Riely G**, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2016 Apr 11. PMID: 27080216
109. Yu HA, Perez L, Chang Q, Gao SP, Kris MG, **Riely GJ**, Bromberg J. A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. *J Thorac Oncol.* 2016 Sep 6. PMID: 27613527
110. Borsu L, Intrieri J, Thampi L, Yu H, **Riely G**, Nafa K, Chandramohan R, Ladanyi M, Arcila ME. Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples. *J Mol Diagn.* 2016 Nov;18(6):903-911. PMID: 27631691
111. Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, Plodkowski A, Ginsberg MS, **Riely GJ**, Rudin CM, Ladanyi M, Kris MG. Cabozantinib in patients with advanced RET-rearranged non-smallcell

lung cancer: an open-label, single-centre, phase 2, single-arm trial. *Lancet Oncol.* 2016 Nov 4. PMID: 27825636

112. Shepherd A, **Riely G**, Detterbeck F, Simone CB 2nd, Ahmad U, Huang J, Korst R, Rajan A, Rimner A. Brief Report: A Survey of Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. *J Thorac Oncol.* 2016 Nov 19. PMID: 27876674

113. Cunanan KM, Gonen M, Shen R, Hyman DM, **Riely GJ**, Begg CB, Iasonos A. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. *J Clin Oncol.* 2016 PMID: 27893325

114. Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin ES, **Riely GJ**, Harris J, Yan S, Wei G, Oliver J, Patel R, Multani P, Ladanyi M, Drilon A. Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. *Clin Cancer Res.* 2016 Dec 23. PMID: 28011461

115. Halpenny DF, Plodkowski A, **Riely G**, Zheng J, Litvak A, Moscovitz C, Ginsberg MS. Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations? *Clin Imaging.* 2016 Nov 30;42:147-151. PMID: 28012356

116. Yu HA, Sima C, Feldman D, Liu LL, Vaitheesvaran B, Cross J, Rudin CM, Kris MG, Pao W, Michor F, **Riely GJ**. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. *Ann Oncol.* 2016 Oct 25. PMID: 28073786

117. Halpenny DF, McEvoy S, Li A, Hayan S, Capanu M, Zheng J, **Riely G**, Ginsberg MS., Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer: Incidence, radiological features and clinical characteristics. *Lung Cancer.* 2017 Apr;106:33-36. PMID: 28285691

118. Jordan EJ, Kim HR, Arcila ME, Barron DA, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu H, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, **Riely GJ**. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. *Cancer Discov.* 2017 Mar 23. pii: CD-16-1337.

119. Hellmann MD, Hayashi T, Reva B, Yu HA, **Riely GJ**, Adusumilli PS, Travis WD, Wilkins O, Bramletta N, Chandramohan R, Fleischut MH, Kris MG, Robson ME, Arcila ME, Paik PK, Ladanyi M. Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. *JCO Precision Oncology* - published online May 31, 2017

120. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L,

- Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, **Riely GJ**, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med.* 2017 Jun;23(6):703-713. PMID: 28481359
121. Patel SH, Rimmer A, Foster A, Zhang Z, Woo KM, Yu HA, **Riely GJ**, Wu AJ. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib. *Lung Cancer.* 2017 Jun;108:109-114. PMID: 28625621
122. McEvoy SH, Halpenny DF, Viteri-Jusué A, Hayes SA, Plodkowski AJ, **Riely GJ**, Ginsberg MS. Investigation of patterns of nodal metastases in BRAF mutant lung cancer. *Lung Cancer.* 2017 Jun;108:62-65. PMID: 28625649
123. Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, **Riely GJ**, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. *Nat Med.* 2017 Aug;23(8):929-937. PMID: 28714990
124. Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhman N, Robbins PB, Karakunnel J, Rimmer A, Huang J, **Riely GJ**, Hellmann MD. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. *PLoS One.* 2017 Aug 3;12(8):e0182665. PMID: 28771603
125. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, **Riely GJ**, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol.* 2017 Jul. PMID: 28890946
126. Cunanan KM, Iasonos A, Shen R, Hyman DM, **Riely GJ**, Gönen M, Begg CB. Specifying the True- and False-Positive Rates in Basket Trials. *JCO Precision Oncology* - published online November 3, 2017
127. Arbour KC, Kris MG, **Riely GJ**, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. *Cancer* 2018 Jan 1;124(1):105-109. PMID: 28940498
128. Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, **Riely GJ**. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant NonSmall Cell Lung Cancer. *Clin Cancer Res.* 2018 Jan 15;24(2):334-340. PMID: 29089357 PMID: 28940498
129. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A,

- Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, **Riely GJ**, Schultz N, Hellmann MD. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With NonSmall-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. *J Clin Oncol*. 2018 Jan 16;JCO2017753384. doi: 10.1200/JCO.2017.75.3384. PMID: 29337640
130. Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, **Riely GJ**, Ladanyi M. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. *Clin Cancer Res*. 2018 Jul 1;24(13):3108-3118. PMID: 29530932
131. Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, **Riely GJ**, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G. Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. *Cancer Discov*. 2018 Jun;8(6):686-695. PMID: 29610121
132. Montecalvo J, Chang J, Rekhtman N, Antonescu CR, Bains MS, Fabbri N, Plodkowski AJ, **Riely GJ**, Travis WD, Sauter JL. Type A thymoma presenting with bone metastasis. *Histopathology*. 2018 Oct;73(4):701-703. PMID: 29855070
133. Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, **Riely GJ**, Politi K, Varmus H, Ladanyi M. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. *Proc Natl Acad Sci U S A*. 2018 Jun 26;115(26) PMID: 29875142
134. Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ignatius Ou SH, Shaw AT, **Riely GJ**. Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. *J Thorac Oncol*. 2018 Oct;13(10):1530-1538.PMID: 29935304
135. Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, **Riely GJ**, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Ado-Trastuzumab Emtansine for Patients With HER2Mutant Lung Cancers: Results From a Phase II Basket Trial. *J Clin Oncol*. 2018 Jul 10 PMID: 29989854
136. Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, **Riely GJ**, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O. Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET-Rearranged Lung Cancers. *J Thorac Oncol*. 2018 Oct;13(10):1595-1601. PMID: 30017832

137. Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, **Riely GJ**, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. *ESMO Open*. 2018 Jul 12;3(5):e000364. PMID: 30018815
138. Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, **Riely GJ**, Yu H, Hellmann MD. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. *Clin Cancer Res*. 2018 Jul 25. PMID: 30045933
139. Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, **Riely GJ**, Besse B, Hellmann MD. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2018 Oct 1;36(28):2872-2878. PMID: 30125216
140. Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin MD, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, **Riely GJ**, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A. PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers. *Ann Oncol*. 2018 Oct 1;29(10):2085-2091. PMID: 3016537
141. Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, **Riely GJ**, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA. Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. *JCO Precision Oncology* - published online September 4, 2018
142. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, **Riely GJ**, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol*. 2018 Dec;19(12):1654-1667. PMID: 30413378
143. Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, **Riely GJ**, Rusch VW, Jones DR, Rimmer A, Rudin CM, Isbell JM, Li BT. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. *J Natl Cancer Inst*. 2018 Nov 28. PMID: 30496436
144. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, **Riely GJ**, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinger IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff

- CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet.* 2019 Feb;51(2):202-206. PMID: 30643254
145. Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, **Riely GJ**, Arcila ME, Somwar R, Ladanyi M. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. *J Thorac Oncol.* 2019 May;14(5):802-815. PMID: 30831205
146. Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, **Riely GJ**, Yu HA, Hellmann MD. Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib. *Ann Oncol.* 2019 May 1;30(5):839-844. PMID: 30847464
147. Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, **Riely GJ**, Aravanis A, Oxnard GR. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. *Ann Oncol.* 2019 Apr 1;30(4):597-603. PMID: 30891595
148. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, **Riely GJ**, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol.* 2019 Jun 1;37(16):1370-1379. PMID: 30892989
149. Shen R, Martin A, Ni A, Hellmann M, Arbour KC, Jordan E, Arora A, Ptashkin R, Zehir A, Kris MG, Rudin CM, Berger MF, Solit DB, Seshan VE, Arcila M, Ladanyi M, **Riely GJ**. Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas, *JCO Precision Oncology*, March 28, 2019. PMID: 31008437
150. Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, **Riely GJ**, Somwar R, Ladanyi M. Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer. *JCO Precis Oncol.* 2019;3. Epub 2019 May 10. PMID: 31157314
151. Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, **Riely GJ**, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. *JCO Precis Oncol.* 2019;3. PMID: 31192313
152. Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, **Riely GJ**, Yu H, Hellmann MD. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. *Clin Cancer Res.* 2019 Feb 1;25(3):1063-1069. PMID: 30045933
153. Drilon A, Schoenfeld AJ, Arbour KC, Litvak A, Ni A, Montecalvo J, Yu HA, Panora E, Ahn L, Kennedy M, Haughney-Siller A, Miller V, Ginsberg M, Ladanyi M, Arcila M, Rekhtman N, Kris MG, **Riely GJ**. Exceptional responders with invasive mucinous

adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. *Cold Spring Harb Mol Case Stud.* 2019 Apr 1;5(2). PMID: 30936194

154. Shaw AT, **Riely GJ**, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol.* 2019 Apr 13. PMID: 30980071

155. Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, **Riely GJ**, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. *Ann Oncol.* 2019 May 14. PMID: 31086949

156. Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, **Riely GJ**, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, Rudin CM, Yu HA. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. *J Thorac Oncol.* 2019 Jun 19. PMID: 31228622

2. Reviews/Editorials/Invited Commentary

1. **Riely GJ**, Pao W. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important? *Cancer Biol Ther.* 2005;4(10):1096-1097. PMID: 16294020.

2. **Riely GJ**, Pao W, Miller VA. Selection of Patients for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. *Lung Cancer Updates.* 2005;5(1):1-8. PMID:

3. **Riely GJ**, Miller VA. Bronchioloalveolar Carcinoma. In: Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, editors. *Textbook of Uncommon Cancer.* West Sussex, England: John Wiley & Sons, Ltd.; 2006.

4. **Riely GJ**, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. *Clin Cancer Res.* 2006;12(24):7232-7241. PMID: 17189394.

5. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, **Riely GJ**, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. *Clin Cancer Res.* 2007;13(15 Pt 2):s4583-4588. PMID: 17671145.

6. **Riely GJ**, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. *Clin Cancer Res.* 2007;13(15 Pt 2):s4623-4627. PMID: 17671153.

7. Garcia J, **Riely GJ**, Nafa K, Ladanyi M. KRAS mutational testing in the selection of patients for EGFR-targeted therapies. *Semin Diagn Pathol.* 2008;25(4):288-294. PMID: 19013894.

8. Huang J, **Riely GJ**, Rosenzweig KE, Rusch VW. Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy? *Ann Thorac Surg*. 2008;85(2):365-367. PMID: 18222226.
9. Lynch TJ, Jr., Blumenschein GR, Jr., Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, **Riely GJ**, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. *J Thorac Oncol*. 2008;3(6 Suppl 2):S107-112. PMID: 18520291.
10. **Riely GJ**. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *J Thorac Oncol*. 2008;3(6 Suppl 2):S146-149. PMID: 18520300.
11. **Riely GJ**. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. *Lung Cancer*. 2008;60 Suppl 2:S19-22. PMID: 18513580.
12. **Riely GJ**, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. *J Mol Diagn*. 2008;10(6):493-495. PMCID: 2570631. PMID: 18832458.
13. **Riely GJ**, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. *Proc Am Thorac Soc*. 2009;6(2):201-205. PMID: 19349489.
14. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jr., Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. Non-small cell lung cancer. *J Natl Compr Canc Netw*. 2010;8(7):740-801. PMID: 20679538.
15. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jr., Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Swanson SJ, Wood DE, Yang SC. Thymic malignancies. *J Natl Compr Canc Netw*. 2010;8(11):1302-1315. PMID: 21081786.
16. Jackman D, Pao W, **Riely GJ**, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *J Clin Oncol*. 2010;28(2):357-360. PMID: 19949011.
17. **Riely GJ**. Lung cancer in 'Never-smokers': molecular factors trump risk factors. *Oncology (Williston Park)*. 2010;24(1):38, 40. PMID: 20187319.
18. **Riely GJ**, Huang J. Induction therapy for locally advanced thymoma. *J Thorac Oncol*. 2010;5(10 Suppl 4):S323-326. PMID: 20859127.
19. Girard N, Lal R, Wakelee H, **Riely GJ**, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. *J Thorac Oncol*. 2011;6(7 Suppl 3):S1749-1755. PMID: 21847058.

20. **Riely GJ.** Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors. *J Thorac Oncol.* 2011;6(11 Suppl 4):S1803-1804. PMID: 22005537.
21. **Riely GJ,** Chaft JE, Ladanyi M, Kris MG. Incorporation of crizotinib into the NCCN guidelines. *J Natl Compr Canc Netw.* 2011;9(12):1328-1330. PMID: 22157552.
22. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, **Riely G,** Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Yang PC, Gould M. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. *Proc Am Thorac Soc.* 2011;8(5):381-385. PMID: 21926387.
23. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, **Riely GJ,** Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol.* 2011;6(2):244-285. PMID: 21252716.
24. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, **Riely GJ,** Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant pleural mesothelioma. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw.* 2012;10(1):26-41. PMID: 22223867.
25. **Riely GJ,** Huang J, Rimmer A. Multidisciplinary Management of Thymic Carcinoma, ASCO 2012 Educational Book. 466-470
26. Yu HA, **Riely GJ.** Who should receive EGFR tyrosine-kinase inhibitors?, *Lancet Oncol* 2012 Nov;13(11):1074-6.
27. Yu HA, **Riely GJ.** Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. *J Natl Compr Canc Netw.* 2013 Feb 1;11(2):161-9.
28. Travis WD, Brambilla E, **Riely GJ.** New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. *J Clin Oncol.* 2013 Mar 10;31(8):992-1001.
29. Ettinger DS, **Riely GJ,** Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Thymomas and thymic carcinomas. *J Natl Compr Canc Netw.* 2013 May 1;11(5):562-76.

30. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenk MC, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 2.2013. *J Natl Compr Canc Netw*. 2013 Jun 1;11(6):645-53.
31. **Riely GJ**, Travis WD. Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma? *Eur Respir J*. 2014 May;43(5):1240-2. PMID: 24789948
32. Yu HA, **Riely GJ**, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. *Clin Cancer Res*. 2014 Dec 1;20(23):5898-907. PMID: 25303979
33. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. *J Natl Compr Canc Netw*. 2014 Dec;12(12):1738-61. PMID: 25505215
34. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 6.2015. *J Natl Compr Canc Netw*. 2015 May;13(5):515-24. PMID: 25964637
35. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. **Riely GJ**, Yu HA. *Clin Cancer Res*. 2015 May 15;21(10):2221-6. doi: 10.1158/1078-0432.CCR-14-3154. PMID: 25979928
36. Beyond "second-line" in non-small cell lung cancer: therapy and supportive care. Martins RG, Reynolds CH, **Riely GJ**. *Am Soc Clin Oncol Educ Book*. 2015;35:e414-8. doi: 10.14694/EdBook_AM.2015.35.e414. PMID: 25993204
37. **Riely GJ**. Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations. *Clin Adv Hematol Oncol*. 2016 Jan;14(1):41-5. PMID: 27057667
38. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, **Riely GJ**, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. *J Natl Compr Canc Netw*. 2016 Mar;14(3):255-64. PMID: 26957612

39. Waqar SN, Bonomi PD, Govindan R, Hirsch FR, **Riely GJ**, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. *J Thorac Oncol*. 2016 Jul 8. [Epub ahead of print] PMID: 27401214
40. Arbour KC, **Riely GJ**. Diagnosis and Treatment of Anaplastic Lymphoma KinasePositive Non-Small Cell Lung Cancer. *Hematol Oncol Clin North Am*. 2017 Feb;31(1):101111.
41. Lin JJ, **Riely GJ**, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. *Cancer Discov*. 2017 Feb;7(2):137-155. PMID: 28122866
42. Dagogo-Jack I, Shaw AT, **Riely GJ**. Optimizing Treatment for Patients with ALK Positive Lung Cancer. *Clin Pharmacol Ther*. 2017 Feb 9. PMID: 28182271
43. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, **Riely GJ**, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2017 Aug 14: PMID: 28806116
44. Arbour KC, **Riely GJ**. Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer. *Cancer*. 2018 Jun 1;124(11):2272-2275. PMID: 29645085
45. Smith TJ, Hanna N, Johnson D, Baker S Jr, Biermann WA, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, **Riely GJ**, Schiller JH, Schneider BJ, Tashbar J, Temin S, Masters G. Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. *J Oncol Pract*. 2017 Dec;13(12):780783. PMID: 28981389
46. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel SP, Reckamp K, **Riely GJ**, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. *J Natl Compr Canc Netw*. 2018 Jul;16(7):807-821. PMID: 30006423